Tag:
CV Therapeutics
Latest Headlines
Latest Headlines
Astellas drops bid for CV Therapeutics
There won't be any bidding war for CV Therapeutics. Japan's Astellas Pharma says it won't challenge Gilead Sciences' $1.4 billion offer for CV, which at $20 a share came in $4 over Astellas' bid. And
Gilead inks $1.4B buyout deal for CV Therapeutics
Gilead Sciences has struck a deal to buy CV Therapeutics for $1.4 billion, paying out $20 a share. The deal comes just weeks after Japan's Astellas revealed that it was willing to pay $16 a share for
Astellas targets CV board in buyout bid
So CV Therapeutics won't play? We'll see about that: Astellas Pharma has a bully-boy gleam in its eye. You can almost hear it saying, "You'll play, buster. So help me, you'll play." Rejected in its
Astellas goes hostile in CV bid
Unable to win over the board of director at CV Therapeutics, Japan's Astellas is taking its $16 a share bid straight to shareholders. And that could set the stage for a battle to oust CEO Louis
Astellas still eyeing CV; Sun, Taro start talking
Here's your daily deal update: Astellas Pharma says it plans to keep pursuing CV therapeutics despite its rejection of a $1 billion offer. And Sun Pharmaceutical Industries and Taro Pharmaceutical
Astellas still hot to buy CV after rejection
CV Therapeutics has once again spurned a takeover offer from Astellas Pharma--which has done nothing to blunt the Japanese company's interest in a takeover. CV rejected Astellas' $16 per share cash
CV rejects Astellas' $1B offer--again
Saying the offer "significantly undervalues the company," CV Therapeutics has reviewed and rejected Astellas Pharma's $1 billion unsolicited bid for CV. The offer was originally presented in
CV taking a new look at $1B buyout bid
Last November, the board at CV Therapeutics spurned Astellas' billion-dollar offer for the company. But the market has changed a lot in the past two months, and CV now says that they'll give
CV Therapeutics reconsiders $1B Astellas offer
CV Therapeutics said it has decided to reconsider Tokyo drugmaker Astellas Pharma's buyout offer. The original offer of $1 billion was presented back in November. At $16 per share, the proposition is
Astellas bids $1B for CV Therapeutics
Japan's Astellas Pharma is offering a billion dollars in cash for CV Therapeutics. The bid comes in at $16 a share, a whopping 41 percent premium over yesterday's close. And the pharma company,
